Arachidonic Acid Metabolism - The Inflammatory Cascade
- Source: Arachidonic Acid (AA) is released from membrane phospholipids by Phospholipase A₂ (inhibited by corticosteroids).
- Pathways: AA is metabolized via two main pathways: Cyclooxygenase (COX) and Lipooxygenase (LOX).
- COX Pathway (Prostanoids)
- Prostaglandins (PGI₂, PGE₂): ↑ Vascular permeability & vasodilation, pain, fever.
- Thromboxane A₂ (TXA₂): ↑ Platelet aggregation & vasoconstriction.
- Inhibited by NSAIDs, Celecoxib.
- LOX Pathway (Leukotrienes)
- LTB₄: Neutrophil chemotaxis. (📌 Brings neutrophils to site).
- Cysteinyl-LTs (LTC₄, LTD₄, LTE₄): Bronchoconstriction, ↑ vascular permeability.
- Inhibited by Zileuton, Montelukast.
⭐ Aspirin irreversibly inhibits COX-1 and COX-2 via covalent acetylation, unlike other NSAIDs which are reversible inhibitors.

Cyclooxygenase (COX) Pathway - Prostanoid Production

- Precursor: Arachidonic Acid, released from cell membranes via Phospholipase A₂.
- Key Enzyme: Cyclooxygenase (COX) converts Arachidonic Acid to Prostaglandin H₂ (PGH₂).
- COX-1 (Constitutive): "Housekeeping" roles like gastric protection, renal blood flow, and platelet aggregation.
- COX-2 (Inducible): Upregulated by inflammatory stimuli to produce prostaglandins that mediate pain, fever, and inflammation.
- Products from PGH₂:
- Prostacyclin (PGI₂): Causes vasodilation and inhibits platelet aggregation.
- Thromboxane A₂ (TXA₂): Causes vasoconstriction and promotes platelet aggregation. 📌 Thromboxane Aggregates.
- Prostaglandins (PGE₂, PGD₂): Mediate inflammation, pain, and fever. PGE₂ maintains a patent ductus arteriosus (PDA).
⭐ Aspirin causes irreversible inhibition of COX-1 in platelets, thus blocking TXA₂ synthesis for the entire platelet lifespan (~7-10 days).
Lipoxygenase (LOX) Pathway - Leukotriene Lineage

- Initiating Enzyme: 5-Lipoxygenase (5-LOX) acts on Arachidonic Acid.
- Pathway Inhibitor: Zileuton blocks 5-LOX.
- Key Products & Functions:
- LTB4: Neutrophil chemotaxis, adhesion, and activation. 📌 LTB4 is for Neutrophils (Brings them 4ward).
- Cysteinyl-LTs (LTC4, LTD4, LTE4):
- Intense bronchoconstriction (asthma).
- ↑ Vascular permeability & vasoconstriction.
⭐ Cysteinyl-leukotriene receptor antagonists (e.g., Montelukast, Zafirlukast) are mainstays in asthma therapy, specifically blocking the effects of LTC4, D4, and E4 on bronchial smooth muscle.
Pharmacologic Modulation - Taming the Flames
- Corticosteroids (e.g., Prednisone): Inhibit Phospholipase A₂, blocking the entire cascade upstream. Halts all prostaglandin and leukotriene production.
- NSAIDs: Inhibit cyclooxygenase (COX) enzymes.
- Non-selective (Aspirin, Ibuprofen): Block both COX-1 and COX-2.
- COX-2 Selective (Celecoxib): Target inflammation with less risk of gastric ulcers.
- Leukotriene Pathway Inhibitors: Primarily for asthma & allergic rhinitis.
- Zileuton: Inhibits 5-Lipoxygenase enzyme.
- Montelukast, Zafirlukast: Block CysLT1 leukotriene receptors.
⭐ Aspirin irreversibly acetylates COX-1 and COX-2. Its effect on platelets is permanent for the platelet's lifespan (~7-10 days), crucial for its cardioprotective role.

High‑Yield Points - ⚡ Biggest Takeaways
- Eicosanoids are signaling molecules derived from arachidonic acid, released from membranes by Phospholipase A2.
- The cyclooxygenase (COX) pathway produces prostaglandins (inflammation, gastric protection) and thromboxanes (platelet aggregation).
- The lipoxygenase (LOX) pathway yields leukotrienes (bronchoconstriction, chemotaxis) and anti-inflammatory lipoxins.
- NSAIDs inhibit COX enzymes; corticosteroids block Phospholipase A2 upstream, hitting both pathways.
- Aspirin causes irreversible COX inhibition, crucial for its antiplatelet effect.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app